{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:44:33Z","timestamp":1769604273769,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s40120-016-0041-9","type":"journal-article","created":{"date-parts":[[2016,2,10]],"date-time":"2016-02-10T04:12:34Z","timestamp":1455077554000},"page":"35-43","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Treatment of Adults with Lennox\u2013Gastaut Syndrome: Further Analysis of Efficacy and Safety\/Tolerability of Rufinamide"],"prefix":"10.1007","volume":"5","author":[{"given":"Rob","family":"McMurray","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Striano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,10]]},"reference":[{"issue":"Suppl 1","key":"41_CR1","first-page":"S3","volume":"13","author":"A Arzimanoglou","year":"2011","unstructured":"Arzimanoglou A, Resnick T. All children who experience epileptic falls do not necessarily have Lennox\u2013Gastaut syndrome\u2026 but many do. Epileptic Disord. 2011;13(Suppl 1):S3\u201313.","journal-title":"Epileptic Disord"},{"issue":"Suppl 1","key":"41_CR2","first-page":"S15","volume":"13","author":"M Kerr","year":"2011","unstructured":"Kerr M, Kluger G, Philip S. Evolution and management of Lennox\u2013Gastaut syndrome through adolescence and into adulthood: are seizures always the primary issue? Epileptic Disord. 2011;13(Suppl 1):S15\u201326.","journal-title":"Epileptic Disord"},{"key":"41_CR3","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1212\/01.wnl.0000303813.95800.0d","volume":"70","author":"T Glauser","year":"2008","unstructured":"Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox\u2013Gastaut syndrome. Neurology. 2008;70:1950\u20138.","journal-title":"Neurology"},{"key":"41_CR4","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1517\/13543784.9.4.829","volume":"9","author":"KK Jain","year":"2000","unstructured":"Jain KK. An assessment of rufinamide as an anti-epileptic in comparison with other drugs in clinical development. Expert Opin Investig Drugs. 2000;9:829\u201340.","journal-title":"Expert Opin Investig Drugs"},{"issue":"Suppl 1","key":"41_CR5","first-page":"S27","volume":"13","author":"T Resnick","year":"2011","unstructured":"Resnick T, Arzimanoglou A, Brown LW, et al. Rufinamide from clinical trials to clinical practice in the United States and Europe. Epileptic Disord. 2011;13(Suppl 1):S27\u201343.","journal-title":"Epileptic Disord"},{"key":"41_CR6","unstructured":"Inovelon\u00ae (rufinamide) Summary of Product Characteristics. Eisai Ltd. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000660\/WC500032937.pdf . Accessed 15 Jan 2016."},{"key":"41_CR7","unstructured":"Banzel\u00ae (rufinamide) Prescribing Information. Eisai Inc. http:\/\/www.banzel.com\/pdfs\/BanzelPI.pdf (2013). Accessed 15 Jan 2016."},{"key":"41_CR8","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ejpn.2014.05.008","volume":"18","author":"G Coppola","year":"2014","unstructured":"Coppola G, Besag F, Cusmai R, et al. Current role of rufinamide in the treatment of childhood epilepsy: literature review and treatment guidelines. Eur J Paediatr Neurol. 2014;18:685\u201390.","journal-title":"Eur J Paediatr Neurol"},{"key":"41_CR9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ejpn.2011.12.012","volume":"16","author":"C St\u00fclpnagel von","year":"2012","unstructured":"von St\u00fclpnagel C, Coppola G, Striano P, M\u00fcller A, Staudt M, Kluger G. First long-term experience with the orphan drug rufinamide in children with myoclonic-astatic epilepsy (Doose syndrome). Eur J Paediatr Neurol. 2012;16:459\u201363.","journal-title":"Eur J Paediatr Neurol"},{"key":"41_CR10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.yebeh.2008.12.013","volume":"14","author":"G Kluger","year":"2009","unstructured":"Kluger G, Kurlemann G, Haberlandt E, et al. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience. Epilepsy Behav. 2009;14:491\u20135.","journal-title":"Epilepsy Behav"},{"key":"41_CR11","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.yebeh.2010.01.005","volume":"17","author":"G Kluger","year":"2010","unstructured":"Kluger G, Haberlandt E, Kurlemann G, et al. First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsy. Epilepsy Behav. 2010;17:546\u20138.","journal-title":"Epilepsy Behav"},{"key":"41_CR12","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.seizure.2010.09.008","volume":"19","author":"G Coppola","year":"2010","unstructured":"Coppola G, Grosso S, Franzoni E, et al. Rufinamide in children and adults with Lennox\u2013Gastaut syndrome: first Italian multicenter experience. Seizure. 2010;19:587\u201391.","journal-title":"Seizure"},{"key":"41_CR13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pediatrneurol.2010.04.003","volume":"43","author":"M Vendrame","year":"2010","unstructured":"Vendrame M, Loddenkemper T, Gooty VD, et al. Experience with rufinamide in a pediatric population: a single center\u2019s experience. Pediatr Neurol. 2010;43:155\u20138.","journal-title":"Pediatr Neurol"},{"key":"41_CR14","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.seizure.2012.02.006","volume":"21","author":"SH Kim","year":"2012","unstructured":"Kim SH, Eun SH, Kang HC, et al. Rufinamide as an adjuvant treatment in children with Lennox\u2013Gastaut syndrome. Seizure. 2012;21:288\u201391.","journal-title":"Seizure"},{"key":"41_CR15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.14581\/jer.12009","volume":"2","author":"JY Kim","year":"2012","unstructured":"Kim JY, Lee CG, Yu HJ, Nam SH, Lee J, Lee M. The efficacy and tolerability of rufinamide in intractable pediatric epilepsy. J Epilepsy Res. 2012;2:33\u20137.","journal-title":"J Epilepsy Res"},{"key":"41_CR16","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.clineuro.2012.09.021","volume":"115","author":"EH Lee","year":"2013","unstructured":"Lee EH, Yum MS, Ko TS. Effectiveness and tolerability of rufinamide in children and young adults with Lennox\u2013Gastaut syndrome: a single center study in Korea. Clin Neurol Neurosurg. 2013;115:926\u20139.","journal-title":"Clin Neurol Neurosurg"},{"key":"41_CR17","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.eplepsyres.2014.08.019","volume":"108","author":"Y Ohtsuka","year":"2014","unstructured":"Ohtsuka Y, Yoshinaga H, Shirasaka Y, Takayama R, Takano H, Iyoda K. Rufinamide as an adjunctive therapy for Lennox\u2013Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan. Epilepsy Res. 2014;108:1627\u201336.","journal-title":"Epilepsy Res"},{"key":"41_CR18","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/epi.12689","volume":"55","author":"S Thome-Souza","year":"2014","unstructured":"Thome-Souza S, Kadish NE, Ramgopal S, et al. Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience. Epilepsia. 2014;55:1235\u201344.","journal-title":"Epilepsia"},{"key":"41_CR19","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1111\/j.1528-1167.2012.03579.x","volume":"54","author":"I Mourand","year":"2013","unstructured":"Mourand I, Crespel A, Gelisse P. Dramatic weight loss with rufinamide. Epilepsia. 2013;54:e5\u20138.","journal-title":"Epilepsia"},{"key":"41_CR20","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.hrthm.2012.01.006","volume":"9","author":"R Schimpf","year":"2012","unstructured":"Schimpf R, Veltmann C, Papavassiliu T, et al. Drug-induced QT-interval shortening following antiepileptic treatment with oral rufinamide. Heart Rhythm. 2012;9:776\u201381.","journal-title":"Heart Rhythm"},{"key":"41_CR21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.eplepsyres.2014.11.004","volume":"110","author":"HJ Kim","year":"2015","unstructured":"Kim HJ, Kim HD, Lee JS, Heo K, Kim DS, Kang HC. Long-term prognosis of patients with Lennox\u2013Gastaut syndrome in recent decades. Epilepsy Res. 2015;110:10\u20139.","journal-title":"Epilepsy Res"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-016-0041-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T01:36:10Z","timestamp":1498268170000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40120-016-0041-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,10]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["41"],"URL":"https:\/\/doi.org\/10.1007\/s40120-016-0041-9","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,10]]}}}